is with the Department of Clinical Nutrition, King Saud Medical City, Riyadh, Saudi Arabia.
is with the School of Biosciences Division of Food, Nutrition & Dietetics, University of Nottingham, Nottingham, UK.
Nutr Rev. 2023 Feb 10;81(3):322-332. doi: 10.1093/nutrit/nuac059.
The safety and efficacy of probiotics during severe illness has been a subject of ongoing interest. The impact of probiotics can worsen nutritional status, which could potentially result in a deterioration of the patient's overall life-threatening status.
This systematic review and meta-analysis evaluated the safety and efficacy of probiotics in reducing intensive care unit (ICU)-acquired infections in adult critically ill patients.
PubMed and Cochrane library databases for the period 2011-2020 were searched.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) methodology was used to search for randomized controlled trials that evaluated the use of probiotics among critically ill patients.
No significant difference was observed between probiotics and control groups in terms of the mortality rate (risk ratio 1.13, 95% confidence interval .82 to 1.55, P = .46). Probiotics, however, provided a significant reduction in ICU-acquired infections (risk ratio .73, 95% confidence interval .58 to .93, P = .01).
The use of probiotics seems to play a role in decreasing the incidence of ICU-acquired infections. Also, a potential reduction in terms of the incidence of diarrhea has been reported, with no examples of adverse incidents, suggesting probiotics are safe.
益生菌在重病期间的安全性和有效性一直是人们关注的课题。益生菌的影响可能会恶化营养状况,这可能导致患者整体危及生命的状况恶化。
本系统评价和荟萃分析评估了益生菌在减少成年危重症患者 ICU 获得性感染方面的安全性和有效性。
对 2011 年至 2020 年期间的 PubMed 和 Cochrane 图书馆数据库进行了搜索。
采用系统评价和荟萃分析的首选报告项目(PRISMA)方法搜索评估益生菌在危重病患者中应用的随机对照试验。
益生菌组与对照组在死亡率方面无显著差异(风险比 1.13,95%置信区间.82 至 1.55,P = .46)。然而,益生菌显著降低了 ICU 获得性感染的发生率(风险比.73,95%置信区间.58 至.93,P = .01)。
益生菌的使用似乎在降低 ICU 获得性感染的发生率方面发挥了作用。此外,据报道益生菌还可能降低腹泻的发生率,且无不良反应事件发生,提示益生菌是安全的。